EU PAL-COPD: Evaluation of the ICLEAR-EU intervention to integrate palliative care in the treatment of people with advanced COPD and their family caregivers

EU PAL-COPD：对 ICLEAR-EU 干预措施的评估，将姑息治疗纳入晚期 COPD 患者及其家庭护理人员的治疗中

基本信息

批准号：
10109731
负责人：
金额：
$ 117.53万
依托单位：
LANCASTER UNIVERSITY
依托单位国家：
英国
项目类别：
EU-Funded
财政年份：
2024
资助国家：
英国
起止时间：
2024 至无数据
项目状态：
未结题

来源：
https://gtr.ukri.org/projects?ref=10109731
关键词：
EU PAL COPD Evaluation ICLEAR

项目摘要

Chronic Obstructive Pulmonary Disease (COPD) is a devastating life-limiting lung disease with a high personal and societal burden. Worldwide, COPD is the third leading cause of death. The symptom burden of people with COPD is as severe and burdensome as the symptom burden of people with lung COPD. While palliative care in many countries is available for people with lung COPD, palliative care and good end-of-life care for people with COPD are not well integrated into their treatment by respiratory hospital teams in Europe. The EU PAL-COPD project is a multidisciplinary, interprofessional, international and intersectoral project aiming at evaluating the clinical and cost-effectiveness of the ICLEAR-EU intervention for people with advanced COPD in different healthcare systems in Europe. ICLEAR-EU is a person-centred and family-centred non-pharmacological service intervention in which respiratory teams in the hospital collaborate with interdisciplinary palliative care teams and with primary care to promote shared decision-making and advance care planning, improve symptom treatment and comfort care, and prevent re-hospitalization after an exacerbation. ICLEAR-EU is based on an existing intervention developed and pilot tested in the UK. In EU PAL-COPD, the effectiveness of ICLEAR-EU will be assessed with a stepped wedge cluster RCT in 1,224 people with advanced COPD in 18 hospitals across six European countries. It is hence the first large-scale international trial on systematic integration of palliative care in respiratory care for people with advanced COPD. Cost-effectiveness, robust mixed methods subgroup analyses and in-depth process and implementation evaluations are also included. EU PAL-COPD will improve the well-being and empowerment of people with COPD and their families and advance the state of the art by providing an innovative service model to the complex palliative and end-of-life care needs. User and stakeholder involvement is crucial throughout the project

慢性阻塞性肺病（COPD）是一种毁灭性的、限制生命的肺部疾病，给个人和社会带来沉重负担。在世界范围内，慢性阻塞性肺病是第三大死因。慢性阻塞性肺病患者的症状负担与肺部慢性阻塞性肺病患者的症状负担一样严重和繁重。虽然许多国家都可以为肺部慢性阻塞性肺病患者提供姑息治疗，但欧洲呼吸系统医院团队并未将姑息治疗和良好的临终关怀纳入慢性阻塞性肺病患者的治疗中。 EU PAL-COPD 项目是一个多学科、跨专业、国际和跨部门项目，旨在评估 ICLEAR-EU 干预措施对欧洲不同医疗系统中晚期 COPD 患者的临床和成本效益。 ICLEAR-EU 是一种以人为本、以家庭为中心的非药物服务干预措施，其中医院的呼吸团队与跨学科姑息治疗团队和初级保健团队合作，促进共同决策和预先护理计划，改善症状治疗和舒适度护理，并防止病情恶化后再次住院。 ICLEAR-EU 基于在英国开发和试点测试的现有干预措施。在 EU PAL-COPD 中，将通过阶梯式楔形集群 RCT 评估 ICLEAR-EU 的有效性，该随机对照试验对 6 个欧洲国家 18 家医院的 1,224 名晚期 COPD 患者进行了评估。因此，这是第一个将姑息治疗系统整合到晚期慢性阻塞性肺病患者呼吸护理中的大规模国际试验。还包括成本效益、稳健的混合方法亚组分析以及深入的流程和实施评估。 EU PAL-COPD 将改善慢性阻塞性肺病患者及其家人的福祉和赋权，并通过为复杂的姑息治疗和临终关怀需求提供创新的服务模式来推进最先进的技术。用户和利益相关者的参与在整个项目中至关重要